This biotechnology company programs cell metabolism to optimize biomanufacturing processes. They use metabolic modeling and minimal data to design custom cell culture media, enabling efficient production of advanced therapies.
Funding
€1.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BSMNEUSFounders
Product
Problem
Cell and gene therapy manufacturing faces challenges in optimizing cell culture media for efficient production and desired cell phenotypes. Traditional media development is slow, often taking years, and may not adequately address the complex metabolic requirements of specific cell types and processes. This can lead to suboptimal cell growth, function, and therapeutic efficacy.
Solution
Tolemy Bio provides custom cell culture media design services, leveraging metabolic modeling and minimal data to optimize biomanufacturing processes for cell and gene therapies. The company employs AI and machine learning to analyze metabolite consumption and cell performance data, pinpointing the cells' metabolic state and designing optimized media formulations. This approach enables rapid development of tailored media solutions that enhance cell growth, function, and critical quality attributes (CQAs), ultimately improving the efficiency and efficacy of advanced therapy manufacturing. Tolemy Bio offers an end-to-end solution, including process characterization, model-driven media optimization, and small-batch media manufacturing with rigorous quality control.
Target Audience
Tolemy Bio serves cell and gene therapy manufacturers, including those working with CAR-T, CAR-NK cells, stem cells (HSCs, MSCs, iPSCs), and HEK293 cells producing AAV and LVV.
Features
- AI and ML-driven media optimization using advanced data analytics and proprietary computational frameworks
- Rapid development timelines, delivering optimized media formulations within weeks
- Custom media design tailored to specific cell types, target outcomes, and process needs
- Small-batch media manufacturing for R&D and pre-clinical phases
- Process characterization to map the existing metabolic state of cells
- Optimization of media composition to drive targeted phenotypic changes, such as enhanced growth and improved endurance markers
- In-house quality control and validation to meet stringent requirements
- Milestone-based media licensing to minimize risk